Biographical sketch

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) Kaohsiung Medical College, Kaohsiung, Taiwan Chang-Gung Memorial Hospital, Taipei, Taiwan Maryland General Hospital & Univ. of Maryland Baylor College of Medicine, Houston, Texas A. Positions and Honors
Professional Experience
1992-1993 Postdoctoral Associate, Section of Atherosclerosis/Medicine, Baylor College of
1993-1994 Instructor of Medicine, Baylor College of Medicine, Houston, Texas
1994-2004 Assistant Professor of Medicine, Baylor College of Medicine, Houston, Texas
2004- Associate Professor of Medicine, Baylor College of Medicine, Houston, Texas

Honors and Awards
1) Tarbox Fellowship, Texas Tech University, 1983 to 1986
2) The Methodist Hospital Foundation Award, 1993 to 1994
3) The Virginia and Ernest Cockrell Jr Award, 1994
4) Zeneca Pharmaceuticals Research Award, 1993 to 1995
5) AHA, Texas Affiliate, Grant-In-Aid, 1995 to 1997
6) Texas Medical Center/NASA Cooperative Research Grant, 1995 to 1996
7) AHA, National, Scientist Development Award, 1997 to 2000
8) The Atorvastatin Research Award, 1999 to 2000
9) American Diabetes Association Research Award, 2000 to 2003
10) Pfizer Independent Medical Grant, 2002-2003
11) American Diabetes Association Research Award, 2004 to 2006
12) Pfizer Independent Medical Grant, 2004-2005
13) Philip Morris Research Award, 2005-2008
14) AHA grant reviewer, Western Review Consortium, 2004-2008.

Honors as a Mentor
1) Postdoctoral Fellow, Jeffrey P. Walterscheid, Ph.D., AHA Fellowship, 2006
2) Postdoctoral Fellow, Daming Tang, M.D., Ph.D, NIH Training Grant, 2007

Memberships in Professional Societies
1) American Diabetes Association
2) AHA, Atherosclerosis Council
3) International Atherosclerosis Society
4) American Association for the Advancement of Science
5) The Angiogenesis Society
B. Publications
Selected peer-review publications (in reversed order) *corresponding author
Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH Chang SF, Liao WS, Chen CH, Lee YT.
Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102:933-941. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WSL, Yang CY, Chen CH*. Electronegative LDL impairs vascular endothelial cell integrity in
diabetes by disrupting FGF2 autoregulation. Diabetes. 2008;57:158-166.
Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T, Chang PY, Safi HJ, Yang CY, Chen CH*. Electronegative LDL circulating in smokers impairs endothelial progenitor cell
differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res. 2008;49:33-47.
Yang CH, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA,
Ballantyne CM, Jenniskens FA, Smith CV. Pro-apoptotic low-density lipoprotein subfractions in type II diabetes atherosclerosis. Atherosclerosis. 2007;193:283-91. Cheng J, Cui R, Chen CH, Du J. Oxidized low-density lipoprotein stimulates p53-dependent activation
of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology. 2007;485:2085-2094. Chen CH*, Walterscheid JP. Plaque angiogenesis versus compensatory arteriogenesis in
atherosclerosis. Circ Res. 2006;99:787-789. Chen CH*. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol.
Chen CH*, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: From laboratory evidence to
clinical application. Curr Vasc Pharmacol. 2004;2:33-43 (figure used for cover page). Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT.
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116-2122. Chen CH*, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM,
Henry PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107:2102-2108. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV. Isolation,
characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2003;23:1083–1090. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, Chen CH*. Oxidized low-density lipoprotein
downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation. 2001;104:588-593. Chen CH*, Jiang W, Via D, Luo S, Li TZ, Lee YT, Henry PD. Oxidized low-density lipoproteins inhibit
endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation. 2000;101:171-177. Chen CH*, Volding D. Medicinal foods: cross cultural perspectives. Drugs and Society. 1999;15:49-
Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. Impaired adaptive vascular growth in
hypercholesterolemic rabbit. Atherosclerosis. 1998;139:243-251. Chen CH*, Cartwright J Jr, Li Z, Luo S, Nguyen HH, Gotto AM Jr, Henry PD. Inhibitory effects of
hypercholesterolemia and oxidized LDL on angiogenesis-like endothelial growth in rabbit aortic explants: essential role of basic fibroblast growth factor. Arterioslcer Thromb Vasc Biol. 1997;17:1303-1312. Chen CH*, Henry PD. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by
suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians. 1997;109:351-361. Chen CH*, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jr, Henry PD. Basic fibroblast growth factor
reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. Atherosclerosis. 1995;116:261-268. Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol.
Chen CH*, Williams J, Lutherer LO. 1994. Cerebellar lesions alter autonomic responses to transient
isovolemic changes in arterial pressure. Clin Auton Res. 1994;4:263-272. Henry PD, Chen CH. Inflammatory mechanism of atheroma formation: influence of fluid mechanics and
lipid-derived inflammatory mediators. Am J Hypertens. 1993;6(suppl):328-334. Chen CH, O'Leary EL, Janssen HF, Lutherer LO. 1985. Changes in ambient temperature alter the
blood pressure response to endotoxin and the effectiveness of naloxone. Circ Shock. 1985;16:185-193. Schoenfeld AD, Lox CD, Chen CH, Lutherer LO. Pain threshold changes induced by acute exposure to
ambient temperature. Peptides. 1985;6 (suppl 1):19-22. Lutherer LO, Smith AL, Chen CH, O'Leary EL, Lutherer BC. The effect of angiotensin and vasopressin
blockade separately and in combination with cerebellectomy on recovery from hemorrhagic hypotension. Circ Shock. 1983;10:329-340. Chen L, Chen CH. Cardiac myxomas: a report of two cases. Modern Medicine in Asia 1980;16(12),
Resubmission invited, in revision
Lu J, Yang JH, Walterscheid JP, Chen HH, Yang CY, Suzuki S, Tang D, Burns AR, Chu CS,
Sawamura T, Chen CH*. Mediation of electronegative LDL signaling by LOX-1: a possible
mechanism of atherosclerosis initiation. Circ Res.
Submitted, under review
Tang D, Lu J, Chen HH, Engler DA, Sawamura T, Morrisett JD, Marcelli M, Yang CY, Chen CH*.
Smoker Electronegative LDL induces MMP-2 activity through LOX-1-mediated Ras/Raf/MEK/ERK signaling pathway in human endothelial progenitor cells. Chen CH*, Lu J, Chu CS, Chang A, Chen HH, Tang D, Pownall HJ, Ballantyne CM, Yang CY.
Atorvastatin compliance reduces atherogenic electronegative LDL and prevents its recurrence.
C. Research Support
a) Ongoing Research Support
1. Research Award PI: Chen, Chu-Huang
Philip Morris Inc. Atherogenic mechanisms and potential treatments of a highly electronegative, mildly oxidized low-density lipoprotein subfraction circulating in smoking subjects The goal is to analyze atherogenic LDL subfractions in the plasma of smoking subjects and to examine whether these LDL subfractions can be eliminated or reduced pharmacologically. 2. RO-1 U01 DK-57177 PI: Foreyt, John P. 09/01/1999−08/31/2008 National Institutes of Health/NIDDK
Lookahead: Study of Health Outcomes of Weight-Loss
Role: Co-investigator
3. Training Grant T32 HL07812-0181 PI: Morrisett, Joel D. 07/01/1997−06/30/2008 National Institutes of Health Training Grant in Atherosclerosis and Vascular Biology The major goals of this project are to equip a cadre of bright, young biomedical scientists with the skills that will enable them to conduct state-of-the-art basic and clinical research in the area of atherosclerosis/vascular biology. The ultimate goal is to train both predoctoral students and postdoctoral fellows to develop new, creative and effective approaches for the prevention and treatment of atherosclerosis. Role: Co-investigator 4. Independent Medical Research Grant PI: Chen, Chu-Huang Merck-Schering Plough Pharmaceuticals
Effects of Ezetimibe and Vytorin on Reducing L5 in Patients with Metabolic Syndrome
5. Multi-center clinical trial PI: Foreyt, John 01/01/06 – 12/31/09
Sanofi-Aventis, US, Inc.
Protocol No. EFC5107 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter study to
assess the efficacy and safety of long-term administration of rimonabant in the prevention of Type 2
Diabetes in Patients with prediabetic status.
Role: Co-investigator
6.Multi-center clinical trial PI: Foreyt, John 01/01/07 – 12/31/2008
Orexigen Therapeutics
A Multicenter,Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Safety and
Efficacy of Naltrexone Sustained Release (SR)/ Bupropion Sustained Release (SR) and Placebo in
Subjects with Obesity Participating in a Behavior Modification Program.
Role: Co-investigator

b) Completed Research Support (recent)
1. Research Award, #1-04-RA-13 PI: Chen, Chu-Huang
American Diabetes Association
Phospholipid-mediated vascular endothelial cell apoptosis in hyperlipidemia (in patients with diabetes)

2. Independent Medical Research Grant PI: Chen, Chu-Huang
Pfizer Pharmaceuticals
Role of electronegative LDL in left ventricular hypertrophy and acute coronary syndromes: Efficacy of
atorvastatin in reducing LV mass and risk of sudden cardiac death
c) Pending Support
1. RO-1
National Institutes of Health/NIDDK Structural Characterization and Signal Mapping of an Electronegative Lipoprotein 2. R21 National Institutes of Health/NIDDK Characterization and epidemiologic investigation of a novel electronegative VLDL in diabetic and prediabetic populations


Tratamiento del estreñimiento

Los hábitos dietéticos son fundamentales tanto como prevención como mantenimiento de un buen ritmo intestinal y El tipo de dieta para favorecer un buen ritmo intestinal varía según la edad del niño. ¿ Qué hábitos debemos fomentar en los lactantes pequeños? La lactancia materna siempre es lo mejor. Hay que evitar estimular el esfínter anal con toques para favorecer la defecación.

Material safety data sheet

MATERIAL SAFETY DATA SHEET   1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION 2. COMPOSITION/INFORMATION ON INGREDIENTS Composition Concentration 3. HAZARDS IDENTIFICATION OF PREPARATION Major Health Hazards: The onset of symptoms varies depending upon such factors as the route of absorption and quantity involved. In patients with occupational poisoning, skin symptom

Copyright © 2010 Medicament Inoculation Pdf